Fox Entertainment has recently confirmed that a U.S. remake of the Italian medical drama Doc – Nelle Tue Mani is currently in the works. The American version will be simply called Doc and it will broadcast on the network channel Fox, which has given it a script-to-series order, and is produced by Fox Entertainment and Sony Pictures Television, the latter having acquired the series’ international rights in 2020.
The one-hour medical drama will be penned by writer Barbie Kligman, already behind many hit series, such as CSI: NY, Private Practice, FBI, and The Vampire Diaries. She is also set to be showrunner and will executive produce along with non-writing producers Hank Steinberg and Erwin Stoff. This project is being developed as the network is still deciding whether or not to renew its current medical drama series, The Resident, which just ended its sixth season.
According to the logline, the Fox series will follow Dr. Amy Elias, Chief of Internal & Family Medicine, who is forced to return to the hospital as an intern after a car accident caused her a brain injury and amnesia, erasing the last eight years of her life from her memory. Completely unaware of a tragedy in her personal life and with no recollection of the incredible medical knowledge that she had built up over the years, she has to start all over again and rebuild her life in the process.
The Italian original series, co-produced by Lux Vide and Rai Fiction for the free-to-air channel Rai 1, centred on a male doctor instead and was inspired by a true story: in 2013, former Lodi and Codogno E.R. Chief Pierdante Piccioni was involved in a car accident which led to him losing memory of the previous twelve years. Piccioni also published a book about this major event in his life, called “Meno Dodici”, which the TV series drew inspiration from, too.
Doc – Nelle Tue Mani, created by Francesco Arlanch and Viola Rispoli, debuted in 2020 with its first season and was the most-watched series in the last 13 years in Italy, with an approximate 30% average share (compared to the network’s average 25%). This amazing result led to it being renewed for a second season, which premiered in 2022 with similar ratings. A third season is expected to air in 2024.